Silexion Therapeutics to Present at HC Wainright's 26th Annual Global Investment Conference

GRAND CAYMAN, Cayman Island, Sept. 3, 2024 (GLOBE NEWSWIRE) — Silexion Therapeutics Corp. (“Silexion” or the “Company”), a clinical-stage biotechnology company focused on oncology, today announced that the Company’s management will attend and present at the HC Wainwright 26th Annual Global Investment Conference to be held September 9-11, 2024 at the Lotte New York Palace Hotel in New York, NY.

A corporate presentation will be available here upon request beginning Monday, September 9 at 7:00 a.m. ET. Silexion’s management team will be available for one-on-one meetings During the conference, interested investors can contact their HC Wainwright representative. A replay of the presentation will be posted on the Silexion website on the Presentation & Events page of the Investors section for 90 days, when available.

About Silexion Therapeutics

Silexion Therapeutics is a pioneering clinical-stage, oncology-focused biotechnology company focused on developing innovative treatments for unsatisfactorily treated solid tumors harboring the mutated KRAS oncogene, which is widely considered the most prevalent oncogenic gene driver in human cancers. The Company conducted a Phase 2a clinical trial with its first-generation product, which demonstrated a positive trend compared to control chemotherapy alone. Silexion is committed to pushing the boundaries of therapeutic advancement in oncology and advancing its lead product candidate for locally advanced pancreatic cancer.

Contacts
Silexion Therapeutics Corp
Ms. Mirit Horenshtein Hadar, CFO
[email protected]